This website is intended for UK healthcare professionals only
Prescribing information can be found here

Exploratory Renal Outcomes

In patients with who do not meet the criteria for diabetic kidney disease (eGFR >60 mL/min/1.73m2, albumin creatinine ratio [ACR] >30 mg/mmol), Invokana reduces protein in the urine and the risk of Major Adverse Renal Events (MARE)…

Learn more about the CREDENCE study and renal benefits in T2DM patients with DKD
Reduce protein

…while stabilising eGFR levels for the long term.

With standard of care, eGFR declines over time. After an initial fall in mean eGFR during the first 4 weeks of treatment, Invokana stabilises eGFR levels for the long term. 1

References
  1. Neal B, et al. N Engl J Med. 2017;377(7):644-57
  2. Reference 16